MXPA06003122A - Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. - Google Patents

Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.

Info

Publication number
MXPA06003122A
MXPA06003122A MXPA06003122A MXPA06003122A MXPA06003122A MX PA06003122 A MXPA06003122 A MX PA06003122A MX PA06003122 A MXPA06003122 A MX PA06003122A MX PA06003122 A MXPA06003122 A MX PA06003122A MX PA06003122 A MXPA06003122 A MX PA06003122A
Authority
MX
Mexico
Prior art keywords
methods
pharmaceutical compositions
alkylidene
antagonist
vitamin
Prior art date
Application number
MXPA06003122A
Other languages
English (en)
Inventor
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA06003122A publication Critical patent/MXPA06003122A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion se refiere a composiciones farmaceuticas y a procedimientos de tratamiento que comprenden administrar a un paciente en necesidad del mismo una combinacion de un derivado de 2-alquilliden -19-nor-vitamina D y un agonista/antagonista de estrogenos o una sal o profarmaco farmaceuticamente aceptable del mismo. Particularmente, la presente invencion se refiere a composiciones farmaceuticas y a procedimientos de tratamiento que comprenden administrar a un paciente en necesidad del mismo 2-metilen -19-nor -20(S)-1a, 25-dihidroxivitamina D3 y (-)-cis-6 -fenil-5 -[4-(2-pirrolidin -1-il-etoxi) -fenil]-5, 6, 7, 8-tetrahidronaftalen -2-ol o una sal o profarmaco farmaceuticamente aceptable del mismo.
MXPA06003122A 2003-09-19 2004-09-06 Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos. MXPA06003122A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452103P 2003-09-19 2003-09-19
PCT/IB2004/002900 WO2005027924A1 (en) 2003-09-19 2004-09-06 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist

Publications (1)

Publication Number Publication Date
MXPA06003122A true MXPA06003122A (es) 2006-05-31

Family

ID=34375516

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06003122A MXPA06003122A (es) 2003-09-19 2004-09-06 Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.

Country Status (16)

Country Link
US (1) US20050070512A1 (es)
EP (1) EP1667692A1 (es)
JP (1) JP2007505881A (es)
KR (1) KR20060040746A (es)
CN (1) CN100496501C (es)
AU (1) AU2004273658A1 (es)
BR (1) BRPI0414448A (es)
CA (1) CA2539361A1 (es)
CO (1) CO5670328A2 (es)
IL (1) IL173621A0 (es)
MX (1) MXPA06003122A (es)
NO (1) NO20061702L (es)
RU (1) RU2331425C2 (es)
TW (1) TW200522967A (es)
WO (1) WO2005027924A1 (es)
ZA (1) ZA200601237B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
EP1694333A2 (en) * 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
EP1689412A4 (en) 2003-11-25 2009-03-11 Wisconsin Alumni Res Found VITAMIN D ANALOGUE FOR THE PREVENTION AND TREATMENT OF ADIPOSITAS
ATE554774T1 (de) * 2005-02-11 2012-05-15 Wisconsin Alumni Res Found 2-methylen-19-nor-(20s-24epi)-1alpha,25- dihydrovitamin-d2
WO2006086613A2 (en) * 2005-02-11 2006-08-17 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR- (20S-24S) - 1α, 25-D IHYDROXYVITAMIN-D2
AU2006230296B2 (en) * 2005-03-29 2011-07-07 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(23s)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone and 2-methylene-19-nor-(23R)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
EP1991233A4 (en) * 2006-02-17 2009-07-01 Avalon Pharmaceuticals Hydroxypiperidine derivatives and their use
WO2008133975A1 (en) * 2007-04-26 2008-11-06 Avalon Pharmaceuticals Multi-ring compounds and uses thereof
AU2011232633B2 (en) 2010-03-23 2014-05-29 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
WO2011119622A1 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (es) * 1962-09-13
US3822287A (en) * 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
EP0002097B1 (en) * 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
DE3762617D1 (de) * 1986-09-11 1990-06-13 Nat Res Dev Tamoxifenderivate.
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 2−位に置換基を有する19−ノル−ビタミンd3 化合物
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5780497A (en) * 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US5985910A (en) * 1996-04-19 1999-11-16 American Home Products Corporation 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
AUPO727097A0 (en) * 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
CA2416194C (en) * 2000-07-14 2009-10-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
JP2004530684A (ja) * 2001-05-10 2004-10-07 メルク エンド カムパニー インコーポレーテッド エストロゲン受容体モジュレーター
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
US7259143B2 (en) * 2002-09-05 2007-08-21 Wisconsin Alumni Research Foundation Method of extending the dose range of vitamin D compounds

Also Published As

Publication number Publication date
RU2331425C2 (ru) 2008-08-20
CN1852720A (zh) 2006-10-25
CA2539361A1 (en) 2005-03-31
AU2004273658A1 (en) 2005-03-31
CO5670328A2 (es) 2006-08-31
KR20060040746A (ko) 2006-05-10
JP2007505881A (ja) 2007-03-15
EP1667692A1 (en) 2006-06-14
US20050070512A1 (en) 2005-03-31
RU2006107652A (ru) 2007-10-27
WO2005027924A1 (en) 2005-03-31
IL173621A0 (en) 2006-07-05
CN100496501C (zh) 2009-06-10
NO20061702L (no) 2006-06-19
BRPI0414448A (pt) 2006-11-14
TW200522967A (en) 2005-07-16
ZA200601237B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
MY148125A (en) Compounds
TW200736223A (en) N-(pyridin-2-yl)-sulfonamide derivatives
NO20061702L (no) Farmasoytiske sammensetninger og fremgangsmater omfattende kombinasjoner av 2-alkyliden-19-nor-vitamin D derivater og en ostrogen agonist/antagonist
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
MY162174A (en) Azetidines mek inhibitors for the treatment of proliferative diseases
PL373001A1 (en) Combination of azelastine and steroids
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
NO20062004L (no) Forlenget frigjoring farmasoytiske blandinger omfattene aplindor og derivater derav
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
AR041089A1 (es) Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
TW200606164A (en) New compounds
BRPI0413186A (pt) composição de fexofenadina e processo para preparação da mesma
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
TW200800984A (en) New compounds
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
TW200732304A (en) Piperidine derivatives
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
UA92463C2 (ru) Производные пиримидинсульфонамида как модуляторы рецепторов хемокина
WO2005007642A3 (en) Novel azaheterocyclic amides useful for treating pain
WO2004041190A3 (en) Composition for the treatment of macular degenration

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION.*

FA Abandonment or withdrawal